JP2006514684A - Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物 - Google Patents

Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物 Download PDF

Info

Publication number
JP2006514684A
JP2006514684A JP2005502202A JP2005502202A JP2006514684A JP 2006514684 A JP2006514684 A JP 2006514684A JP 2005502202 A JP2005502202 A JP 2005502202A JP 2005502202 A JP2005502202 A JP 2005502202A JP 2006514684 A JP2006514684 A JP 2006514684A
Authority
JP
Japan
Prior art keywords
phenyl
compound
independently
occurrence
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005502202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514684A5 (https=
Inventor
カオ，　ジンロン
ファーイ カオ，
ジェレミー グリーン，
クライグ マーヘフカ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2006514684A publication Critical patent/JP2006514684A/ja
Publication of JP2006514684A5 publication Critical patent/JP2006514684A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
JP2005502202A 2002-10-30 2003-10-30 Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物 Withdrawn JP2006514684A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42244102P 2002-10-30 2002-10-30
US47643303P 2003-06-06 2003-06-06
US47669103P 2003-06-06 2003-06-06
US47990303P 2003-06-19 2003-06-19
PCT/US2003/034319 WO2004041813A1 (en) 2002-10-30 2003-10-30 Compositions useful as inhibitors of rock and other protein kinases

Publications (2)

Publication Number Publication Date
JP2006514684A true JP2006514684A (ja) 2006-05-11
JP2006514684A5 JP2006514684A5 (https=) 2006-12-21

Family

ID=32314959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005502202A Withdrawn JP2006514684A (ja) 2002-10-30 2003-10-30 Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物

Country Status (14)

Country Link
US (1) US20040122016A1 (https=)
EP (1) EP1558607B1 (https=)
JP (1) JP2006514684A (https=)
KR (1) KR20050088283A (https=)
AR (1) AR043057A1 (https=)
AT (1) ATE466855T1 (https=)
AU (1) AU2003288956A1 (https=)
CA (1) CA2504320A1 (https=)
DE (1) DE60332475D1 (https=)
MX (1) MXPA05004689A (https=)
NO (1) NO20052595L (https=)
NZ (1) NZ540161A (https=)
TW (1) TW200416221A (https=)
WO (1) WO2004041813A1 (https=)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531757A (ja) * 2004-03-30 2007-11-08 カイロン コーポレイション 抗癌剤としての置換チオフェン誘導体
JP2007535551A (ja) * 2004-04-28 2007-12-06 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物
WO2008050600A1 (en) * 2006-10-25 2008-05-02 Neugen Pharma Inc. Therapeutic or preventive agent for intractable disease based on oxidative stress-mediated cell death as molecular background
JP2009544755A (ja) * 2006-07-28 2009-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
JP2011529458A (ja) * 2008-07-30 2011-12-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 置換ピリジン類およびｇｓｋ３阻害剤としてのそれらの使用
JP2012521407A (ja) * 2009-03-23 2012-09-13 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としてのチエノピリミジンジオン誘導体
JP2013536818A (ja) * 2010-09-01 2013-09-26 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 除草活性を有するケトスルタム類及びジケトピリジン類
JP2015164927A (ja) * 2009-12-14 2015-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌などの疾患を処置するためのチアゾール誘導体
JP2017516859A (ja) * 2014-05-30 2017-06-22 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ １，３，４−チアジアゾール化合物および癌を治療する際のその使用
JP2017537948A (ja) * 2014-12-17 2017-12-21 ジャンキョテックス スイス エスアーＧｅｎｋｙｏｔｅｘ Ｓｕｉｓｓｅ Ｓａ Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体
JP2019504900A (ja) * 2016-02-16 2019-02-21 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー プロテインキナーゼ阻害剤である新規な２，３，５−置換チオフェン化合物
JP2020527560A (ja) * 2017-07-12 2020-09-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としてのフェニルアセトアミド
JP2023510743A (ja) * 2020-01-07 2023-03-15 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196106B2 (en) * 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AU2004267094A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors
RU2006111093A (ru) * 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
CA2551611C (en) 2003-12-26 2013-06-25 Kyowa Kirin Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
BRPI0507278A (pt) * 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
EP1753750A1 (en) * 2004-05-20 2007-02-21 Sugen, Inc. Thiophene heteroaryl amines
SG155222A1 (en) * 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
EA012181B1 (ru) * 2004-10-18 2009-08-28 Амген, Инк. Соединения тиадиазола и их применение
EP1814883A1 (en) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
CN101137631A (zh) * 2004-12-03 2008-03-05 转化技术制药公司 杂芳族葡糖激酶激活剂
WO2006137527A1 (ja) 2005-06-23 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. チアゾール誘導体
WO2007037543A1 (ja) * 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
WO2007053503A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
WO2007053657A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007053662A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
CA2627910A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
MY149143A (en) * 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
US8211925B2 (en) 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
ATE478865T1 (de) 2006-05-12 2010-09-15 Vertex Pharma Selektive rock-proteinkinasehemmer und ihre verwendung
US20080045560A1 (en) * 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
KR20090053923A (ko) * 2006-09-22 2009-05-28 노파르티스 아게 헤테로시클릭 유기 화합물
WO2008124000A2 (en) * 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
RS54303B1 (sr) * 2007-07-19 2016-02-29 Lundbeck, H., A/S 5-člani heterociklični amidi i srodna jedinjenja
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
WO2009079008A1 (en) * 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
CA2709883A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
EP2240475B1 (en) 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
US20110038835A1 (en) * 2007-12-21 2011-02-17 The Scripps Research Institute Anilides and analogs as rho kinase inhibitors
JP2011525930A (ja) * 2008-06-26 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害剤
EP2303852A4 (en) * 2008-06-26 2011-12-28 Glaxosmithkline Llc ACTIVITY INHIBITORS AKT
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
US7906553B2 (en) 2008-08-27 2011-03-15 Calcimedica, Inc. Substituted thiophene modulators of intracellular calcium
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010083246A1 (en) 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
MX2011008276A (es) 2009-02-06 2011-12-14 Elan Pharm Inc Inhibidores de quinasa jun n-terminal.
WO2010093849A2 (en) * 2009-02-13 2010-08-19 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
WO2010150927A1 (en) * 2009-06-25 2010-12-29 Sk Holdings Co., Ltd. Pharmaceutical composition for prevention and treatment of cancer diseases comprising benzamide derivatives
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011034962A2 (en) 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2011076732A1 (en) * 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
WO2011076734A1 (en) * 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2011130740A2 (en) * 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
EP2558458B1 (de) 2010-04-16 2017-09-06 Bayer Intellectual Property GmbH Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
RU2576316C2 (ru) 2010-11-03 2016-02-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидная композиция, способ контроля вредителей, способ контроля эндопаразитов, эктопаразитов или обоих и способ усиления жизнестойкости растений
JP6027128B2 (ja) 2011-10-26 2016-11-16 ダウ アグロサイエンシィズ エルエルシー 有害生物防除組成物およびそれに関連した方法
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
BR122014028247A2 (pt) 2012-04-27 2019-05-07 Dow Agrosciences Llc composições pesticidas, processo para controlar praga, uso de uma molécula, processo para aumentar a saúde, rendimento, vigor, qualidade ou tolerância de uma planta e processos para produção de compostos
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2014060381A1 (de) * 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
US9914740B2 (en) 2013-07-02 2018-03-13 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EP3016950B1 (en) 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
JP2016539092A (ja) 2013-10-17 2016-12-15 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
MX2016004941A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
CA2925953C (en) 2013-10-17 2021-11-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3057429A4 (en) 2013-10-17 2017-08-09 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
CA2926095A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
US9029554B1 (en) 2013-10-17 2015-05-12 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
AR098099A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas sinérgicas y los métodos relacionados
EP3060044A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
AR098101A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y métodos relacionados
NZ719776A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
NZ719952A (en) 2013-10-22 2017-05-26 Dow Agrosciences Llc Pesticidal compositions and related methods
AU2014340424B2 (en) 2013-10-22 2017-06-29 Dow Agrosciences Llc Pesticidal compositions and related methods
RU2656894C2 (ru) 2013-10-22 2018-06-07 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и соответствующие способы
US9282740B2 (en) 2013-10-22 2016-03-15 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
US9788545B2 (en) 2013-10-22 2017-10-17 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
US9801383B2 (en) 2013-10-22 2017-10-31 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AR098100A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y los métodos relacionados
TW201517797A (zh) 2013-10-22 2015-05-16 Dow Agrosciences Llc 協同性殺蟲組成物及相關方法（十一）
JP2016535026A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
US9295260B2 (en) 2013-10-22 2016-03-29 Dow Agrosciences Llc Pesticidal compositions and related methods
JP2016534073A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
KR20160074628A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
MX2016005305A (es) 2013-10-22 2017-03-01 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
WO2015106272A1 (en) * 2014-01-13 2015-07-16 Harki Daniel A Small molecule inhibitors of apobec3g and apobec3b
JP2017523168A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
US9249122B1 (en) 2014-07-31 2016-02-02 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
BR112017000293A2 (pt) 2014-07-31 2017-10-31 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
JP2017525703A (ja) 2014-08-19 2017-09-07 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
AR098113A1 (es) 2014-09-12 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
KR101726819B1 (ko) 2014-10-27 2017-04-13 동아에스티 주식회사 Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2017023684A2 (en) * 2015-07-31 2017-02-09 Progenra, Inc. Covalent irreversible inhibitors of usp7 as anti-cancer agents
CN110325036B (zh) 2016-12-29 2021-10-26 美国陶氏益农公司 用于制备杀虫化合物的方法
JP2020503336A (ja) 2016-12-29 2020-01-30 ダウ アグロサイエンシィズ エルエルシー 殺有害生物化合物の調製方法
US11273154B2 (en) 2017-03-03 2022-03-15 Progenra, Inc. Azole compounds as ubiquitin-specific protease USP7 inhibitors
KR20190122806A (ko) * 2017-03-13 2019-10-30 장피트 조합 치료요법용 약학 조성물
JP2020523363A (ja) * 2017-06-14 2020-08-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ 治療への使用のための二環式複素芳香族アミド化合物
US11174253B2 (en) 2017-08-02 2021-11-16 Alphala Co., Ltd. Compound and pharmaceutical composition containing the same
JP2022552655A (ja) * 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
US12478614B2 (en) * 2020-01-21 2025-11-25 Emory University Inhibitors of glutathione s-transferases (GSTs) and NAD(P)H:quinone oxidoreductase 1 (NQO1), pharmaceutical compositions, and uses in managing cancer
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
TW202334117A (zh) 2020-08-24 2023-09-01 美商達薩瑪治療公司 Ｓａｒｍ１之抑制劑
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
JP2005538056A (ja) * 2002-05-31 2005-12-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 駆虫用および殺虫用のチオフェン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EP1205478A4 (en) * 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
DE60023926T2 (de) * 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
EP1256578B1 (en) * 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
CA2446756C (en) * 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
JP2005538056A (ja) * 2002-05-31 2005-12-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 駆虫用および殺虫用のチオフェン誘導体

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531757A (ja) * 2004-03-30 2007-11-08 カイロン コーポレイション 抗癌剤としての置換チオフェン誘導体
JP2007535551A (ja) * 2004-04-28 2007-12-06 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物
JP2009544755A (ja) * 2006-07-28 2009-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
WO2008050600A1 (en) * 2006-10-25 2008-05-02 Neugen Pharma Inc. Therapeutic or preventive agent for intractable disease based on oxidative stress-mediated cell death as molecular background
JP2011529458A (ja) * 2008-07-30 2011-12-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 置換ピリジン類およびｇｓｋ３阻害剤としてのそれらの使用
JP2012521407A (ja) * 2009-03-23 2012-09-13 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としてのチエノピリミジンジオン誘導体
JP2015164927A (ja) * 2009-12-14 2015-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌などの疾患を処置するためのチアゾール誘導体
JP2013536818A (ja) * 2010-09-01 2013-09-26 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 除草活性を有するケトスルタム類及びジケトピリジン類
JP2017516859A (ja) * 2014-05-30 2017-06-22 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ １，３，４−チアジアゾール化合物および癌を治療する際のその使用
JP2017537948A (ja) * 2014-12-17 2017-12-21 ジャンキョテックス スイス エスアーＧｅｎｋｙｏｔｅｘ Ｓｕｉｓｓｅ Ｓａ Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体
JP2019504900A (ja) * 2016-02-16 2019-02-21 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー プロテインキナーゼ阻害剤である新規な２，３，５−置換チオフェン化合物
JP2020143118A (ja) * 2016-02-16 2020-09-10 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー プロテインキナーゼ阻害剤である新規な２，３，５−置換チオフェン化合物
JP2020527560A (ja) * 2017-07-12 2020-09-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としてのフェニルアセトアミド
JP7206253B2 (ja) 2017-07-12 2023-01-17 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのフェニルアセトアミド
JP2023510743A (ja) * 2020-01-07 2023-03-15 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
JP7490781B2 (ja) 2020-01-07 2024-05-27 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤

Also Published As

Publication number Publication date
TW200416221A (en) 2004-09-01
DE60332475D1 (de) 2010-06-17
AR043057A1 (es) 2005-07-13
AU2003288956A1 (en) 2004-06-07
WO2004041813A1 (en) 2004-05-21
EP1558607B1 (en) 2010-05-05
NZ540161A (en) 2008-03-28
US20040122016A1 (en) 2004-06-24
EP1558607A1 (en) 2005-08-03
NO20052595D0 (no) 2005-05-30
NO20052595L (no) 2005-06-27
KR20050088283A (ko) 2005-09-05
MXPA05004689A (es) 2005-12-05
CA2504320A1 (en) 2004-05-21
ATE466855T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
JP2006514684A (ja) Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物
JP2006514684A5 (https=)
JP5019612B2 (ja) Ｒｏｃｋの阻害剤として有用なアザインドールおよび他のプロテインキナーゼ
US7531556B2 (en) Compositions useful as inhibitors of rock and other protein kinases
RU2350606C2 (ru) Диаминотриазолы, пригодные в качестве ингибиторов протеинкиназ
US7157476B2 (en) Aminofurazan compounds useful as protein kinase inhibitors
US8697911B2 (en) Rho kinase inhibitors
HK1217482A1 (en) Enzyme modulators and therapies
KR20100027188A (ko) 피리다지논 유도체
US7683067B2 (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
KR20070085407A (ko) 단백질 키나아제의 억제제로서 유용한 트리아졸
EP2630144B1 (en) Rho kinase inhibitors
EP1373266A2 (en) (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
US20090203692A1 (en) Novel chemical compounds
HK1086563A (en) Compositions useful as inhibitors of rock and other protein kinases
HK1109567A (en) Triazoles useful as inhibitors of protein kinases
AU2002230365A1 (en) (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060824

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20060824

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060829

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100803

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100831

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130201